Interestingly, GW9662 enhanced the inhibitory effect of the agonist rosiglitazone on breast cancer cells rather than rescuing tumor growth, suggesting that PPARγ activation may not be involved in inhibition of survival and cell growth caused by agonists [72]. Here, PPARG is linked to breast cancer.